Will Pizii

Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.

The combination of toripalimab and chemotherapy displayed promising efficacy results in a phase 2 study.

Certain patients with Wilm's tumor-expressing solid tumors are eligible to be treated with an investigational agent in a phase 1 clinical trial.

In the PIONEER study, clinically meaningful benefit was shown with avapritinib in patients with non-advanced systemic mastocytosis across both primary and secondary end points.

Sanofi has discontinued the clinical development program for amcenestrant due to unsatisfactory results from the phase 3AMEERA-5 trial.

Olaparib in combination with abiraterone and prednisone, or prednisolone may soon be an FDA-approved treatment for adult patients with metastatic castration-resistant prostate cancer.

The phase CANOPY-A study has missed its primary end point of disease-free survival improvement in patients with stages II to IIIA and IIIB completely resected non-small cell lung cancer.

Tisagenlecleucel boosted survival rates in children with B-cell lymphoblastic leukemia. Further research will be planned to examine the data and analyze additional clinical variables.

A study of devimistat in combination with gemcitabine and cisplatin indicated for patients with locally advanced unresectable or metastatic biliary tract cancer has been successfully completed.

Tremelimumab plus durvalumab and chemotherapy displayed improvements in clinical and survival benefit in patients with PD-L1 negative metastatic non–small cell lung cancer.

Erasca has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the anti-EGFR antibody cetuximab.

Acalabrutinib’s new tablet formulation has been granted FDA approval for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and relapsed or refractory mantle cell lymphoma.

Disparities exist for Medicaid-insured patients at centers designated for high-quality care, according to researchers from Yale Cancer Center.

According to Lorenza Di Marco, PhD, immunotherapy treatment can increase the risk of liver rejection in patients with recurrent HCC who have undergone a liver transplant.

In COSMIC-312, reduction in the risk of disease progression or death was achieved with the combination of cabozantinib Plus atezolizumab compatient with sorafenib in patient with hepatocellular carcinoma.

The FDA accepted review for the premarket approval supplement application for the Pan-cancer oncoReveal™ CDx.

Results from the SUMMIT basket study revealed encouraging results with the triplet regimen in patients with HR-positive/HER2-negative MBC compared with other variations and monotherapies of the 3 drugs.

There are several trials with oral SERDs in clinical development for hormone-receptor-positive metastatic breast cancer as both monotherapies and in combination therapy.

Investigators at Tulane University have identified a relationship that linked cancer incidence and cancer risk from air pollution in Louisiana among Black or low-income communities, which were more likely to be affected than other populations.

Results from the primary analysis of the phase 3 COSMIC-313 trial showed significant improvement in progression-free survival in patients with renal cell carcinoma receiving the combination of cabozantinib, nivolumab, and ipilimumab.

Hispanic and Black men are showing higher cancer-specific mortality rates from HPV-associated throat cancer, and most new cases are being diagnosed in White men at a late-stage.

Specific biliary tract cancer clusters have distinct clinical and biologic features which may provide opportunities for therapeutic development.

In the phase 2 MOUNTAINEER study, the investigational combination of tucatinib and trastuzumab achieved durable response in patients with metastatic colorectal cancer.

Improvement in overall survival has been demonstrated with the combination of durvalumab and tremelimumab in patients with unresectable liver cancer treated in the phase 3 HIMALAYA study.

Findings from 2 studies suggest that long-term survival is possible in a significant proportion of patients with a 1p/19q co-deleted oligodendroglioma.

Gilteritinib monotherapy reacts favorably and led to higher rates of composite complete remissions in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia who received prior midostaurin or sorafenib.

In patients with HER2-positive breast cancer, an investigational liquid biopsy was more favorable compared with needle biopsies, a study shows.

A retrospective analysis of next-generation sequencing data showed that the presence of pathogenic POLE mutations correlate with clinical benefit in immune checkpoint inhibitor therapy.

Adding atezolizumab to first-line FOLFOXIRI with bevacizumab is shown to be a safe treatment option and improves progression-free survival in patients with metastatic colorectal cancer.